CHICAGO--(BUSINESS WIRE)--According to Fitch Ratings, the ratings of Teva Pharmaceutical Industries Limited (NYSE: TEVA) and its subsidiaries, including the 'BBB+' long-term Issuer Default Rating, remain on Rating Watch Negative, following its announcement that it will acquire the global generics business of Allergan plc (Allergan; NYSE: AGN) for $40.5 billion. The purchase price consists of $33.75 billion in cash and $6.75 billion in Teva stock. The stock issuance is estimated to represent les
| < Prev | Next > |
|---|
